Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment

Laura García-Otero¹, Marta López¹*, Mariona Guitart-Mampel², Constanza Morén², Anna Goncé¹, Carol Esteve¹, Laura Salazar¹, Olga Gómez¹, Josep Maria Martínez¹, Berta Torres³, Sergi César⁴, Glòria Garrabou², Fàtima Crispi¹, Eduard Gratacós¹

¹ Fetal i+D Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain, 2 Muscle Research and Mitochondrial Function Laboratory, Cellex IDIBAPS, Faculty of Medicine and Health Sciences-University of Barcelona, Internal Medicine Service-Hospital Clinic of Barcelona (Barcelona, Spain) and CIBER-ER, 3 Infectious Diseases Department, Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica (FCRB), Barcelona, Spain, 4 Department of Pediatric Cardiology, Hospital Sant Joan de Déu Barcelona, University of Barcelona, Barcelona, Spain

* lopezro@clinic.cat

Abstract

Background

Mitochondrial toxicity related to maternal combined antiretroviral treatment (cART) may have an impact on the heart of HIV-exposed uninfected (HEU) fetuses. Our objective was to evaluate fetal cardiovascular and mitochondrial biomarkers in HIV pregnancies.

Methods

Prospective cohort including 47 HIV-infected and 47 non HIV-infected pregnancies. Fetal echocardiography was performed at 26–32 weeks of pregnancy. Umbilical cord blood and placental tissue were collected to study mitochondrial DNA content (mtDNA) (ratio 12SrRNA/RNAseP) and mitochondrial function (cytochrome c oxidase, COX, enzymatic activity) normalized by mitochondrial content (citrate synthase, CS).

Results

HEU fetuses showed hypertrophic hearts (left myocardial wall thickness: HIV mean 3.21 mm (SD 0.81) vs. non-HIV 2.72 (0.42), p = 0.012), with signs of systolic and diastolic dysfunction (isovolumic relaxation time: HIV 52.2 ms (8.85) vs. non-HIV 42.5 ms (7.30); p < 0.001). Cord blood mitochondrial content was significantly increased in HIV-exposed fetuses (CS activity: HIV 82.9 nmol/min.mg of protein (SD 40.5) vs. non-HIV 56.7 nmol/min.mg of protein (28.4); p = 0.007), with no differences in mtDNA content and COX activity. Both myocardial and mitochondrial mass parameters were significantly associated with zidovudine exposure.
Conclusions
HEU fetuses showed signs of increased myocardial and mitochondrial mass associated with maternal zidovudine treatment, suggesting a fetal adaptive response to cART toxicity.

Introduction
Perinatal transmission of Human Immunodeficiency Virus (HIV) is mainly prevented by combined antiretroviral treatment (cART) during pregnancy [1]. In 2016, about 76% [60–88%] of pregnant women living with HIV worldwide had access to cART [1–4]. As a result, the number of HIV-exposed uninfected (HEU) children has been on the rise, with health conditions presented, even if mild, having a potentially noteworthy public health impact [5]. Indeed, it is well known that an adverse prenatal environment during the critical period of fetal development might have long lasting consequences on health [6].

HEU children are mainly considered a healthy population, although recent studies have raised concerns regarding their cardiovascular health. Several studies have demonstrated significant changes in the cardiovascular structure and function of HEU offspring from fetal life to adolescence [7–12]. A recent study by our group suggested that fetal cardiac remodeling observed in HIV-infected pregnancies was associated with maternal use of zidovudine [11]. However, the specific mechanism of cardiac remodeling observed in HEU offspring remains to be elucidated. Mitochondrial toxicity related to HIV or cART use during pregnancy may be a potential pathophysiological pathway responsible for these cardiovascular changes.

HIV itself is known to cause mitochondrial DNA (mtDNA) depletion as well as mitochondrial respiratory chain (MRC) disturbances in HIV patients who have never received cART [13]. Moreover, mitochondrial toxicity derived from cART has been widely described in adults, especially as it relates to nucleoside reverse transcriptase inhibitors (NRTIs), which are known to inhibit mtDNA polymerase gamma [14] promoting mitochondrial dysfunction [15] responsible for a wide range of clinical manifestations including myocardiopathy in children and adults [16,17]. During pregnancy, the mitochondrial effects of HIV infection and NRTI exposure have been scarcely assessed with conflicting results [18–20] reporting decreased [21] or increased mtDNA content [20] in HEU children with in utero cART exposure and neonatal zidovudine prophylaxis [21–25]. However, none of these studies have investigated the association between the mitochondrial findings and fetal cardiac changes nor have they assessed the role of different cART regimens on the fetal cardiac remodeling mechanism.

The objective of the present study was to evaluate cardiovascular and mitochondrial biomarkers in HEU fetuses from HIV pregnancies under cART as compared to non-HIV-infected pregnancies. Therefore, we designed a cohort of HIV-exposed and HIV-unexposed pregnancies undergoing fetal echocardiography and we determined cardiac and mitochondrial biomarkers in cord blood and placenta.

Methods
Study design and population
A prospective cohort study was performed in 47 HEU fetuses from HIV-infected pregnant women under CART followed in the Maternal—Fetal Medicine Department at BCNatal (Hospital Clinic and Hospital Sant Joan de Deu) in Barcelona (Spain) from December 2014 to March 2017. The unexposed group included 47 consecutively recruited non-HIV-infected
pregnancies from the same Department accepting to participate. The unexposed group was frequency paired (1:1) with HIV-infected pregnancies by gestational age at fetal echocardiography (± 1 week). Exclusion criteria included multiple pregnancies, diagnosis of fetal malformations or chromosomal abnormalities, delivery before 24 weeks of gestational age as well as perinatal transmission of HIV or familiar history of mitochondrial disease. All individuals were informed, and signed written consent was obtained for inclusion in this study. The study protocol was approved by the Ethical Committee of our hospital (Comité Ético de Investigación del Hospital Clinic de Barcelona (CEIC)) in accordance with the Declaration of Helsinki guidelines. Approval number HCB/2014/0401 ER-01.

The same study protocol was applied in both groups including collection of baseline and perinatal characteristics, third trimester fetal echocardiography and collection of biological samples at delivery (umbilical cord blood and placenta).

Collection of maternal, perinatal and immunovirological characteristics

Maternal demographic and perinatal characteristics were collected by personal interview or review of medical records. Low socioeconomic status was considered when a patient was illiterate or had a primary educational level. Maternal comorbidity was defined as the presence of chronic hypertension [26], pregestational diabetes [27] or autoimmune disorder [28]. Pre-eclampsia was defined as new onset of hypertension (systolic pressure > 140 mmHg and/or diastolic pressure > 90 mmHg) together with more than 300 mg proteins in 24 h urine [29]. Preterm delivery was defined as delivery before 37 weeks of gestation and small for gestational age by birth weight below 10th percentile according to local standards [30]. Perinatal mortality was defined as intrauterine fetal death after 22 weeks of pregnancy or neonatal death within the first 28 days of life [31]. Major neonatal morbidity was defined by the presence of bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia, retinopathy, persistent ductus arteriosus, or sepsis.

The immunovirological and therapeutic parameters of HIV-infected women were also recorded including mode of transmission, presence of previous opportunistic infections, diagnosis of HIV during pregnancy and months of HIV infection at delivery. The CD4 T-cell count was assessed by flow cytometry and plasmatic viral load by HIV-RNA copy quantification (Amplicor HIV Monitor; Roche Diagnostic Systems, Branchburg, New Jersey, USA) during pregnancy. Hemoglobin levels were recorded in the third-trimester blood test to detect potential maternal anemia. Antiretroviral therapy was administered to all HIV-infected pregnant women following local and international guidelines [32,33]. The recommended combinations included two NRTI with either a non-nucleoside reverse-transcriptase inhibitor (NNRTI) or one or more protease inhibitors (PI) or other antiretroviral drugs such as integrase inhibitors (INI). The type and duration of cART before and during pregnancy were also recorded.

Fetal echocardiography

Fetal ultrasonographic examination was performed in all pregnancies at 26–32 weeks of gestation using a Siemens Sonoline Antares (Siemens Medical Systems, Malvern, PA, USA) with 6–4 MHz linear curved-array and 2–10 MHz phased-array probes, including evaluation of estimated fetal weight, feto-placental Doppler and echocardiography. Ultrasounds were performed by maternal—fetal medicine specialists skilled in fetal echocardiography who were blinded to the cART regimen but not to the HIV status. Gestational age was calculated according to first trimester crown-rump length [34]. Fetal weight was estimated following the
Hadlock formula [35]. Feto-placental Doppler evaluation included the calculation of cerebroplacental ratio [36] as a surrogate of placental insufficiency.

Fetal echocardiography included a comprehensive morphometric and functional assessment by two-dimensional, M-mode, conventional and tissue Doppler following a standard protocol. The cardiothoracic ratio was calculated as heart area/thoracic area [37]. Pericardial effusion was evaluated at the midventricular level from a transverse four-chamber view and considered present when exceeding 2 mm [38]. Myocardial wall thicknesses were measured from a 2D transverse four-chamber view at end-systole [39]. The left ejection fraction was obtained from a transverse four-chamber view by M-mode using the Teichholz’s formula [40]. Mitral and tricuspid ring displacement were assessed by M-mode from an apical or basal four-chamber view [41]. Systolic (S’) and early diastolic (E’) annular peak velocities were obtained by spectral real time tissue Doppler at tricuspid and lateral mitral annuli [42]. Left isovolumic and ejection times were obtained placing the Doppler sample volume on the medial wall of the ascending aorta, including the aortic and mitral valve. Valvular clicks in the Doppler wave were used as landmarks. Isovolumic contraction time (ICT) was measured from the closure of the mitral valve to the opening of the aortic valve. Ejection time (ET) was measured from the opening to the closure of the aortic valve. Isovolumic relaxation time (IRT) was measured from the closure of the aortic valve to the opening of the mitral valve [43,44]. Myocardial performance index (MPI) was calculated as follows: (ICT + IRT)/ET [44].

**Cord blood and placental samples collection**

Fetal umbilical cord blood was collected in EDTA tubes immediately after delivery. Plasma was separated by centrifugation at 1500 rcf for 15 min at room temperature and immediately stored at -80˚C until further experimental analysis. In addition, cord blood mononuclear cells (CBMC) were isolated by Ficoll density gradient centrifugation, divided into aliquots and stored at -80˚C until mitochondrial analysis. An estimated platelet count < 25 per lymphocyte/monocyte suggested negligible platelet contamination for the analysis of mitochondrial DNA (mtDNA) content [45].

Placental samples were immediately collected after delivery. Tissue samples of villous parenchyma (1–2 cm$^3$) were selected from three different sites of three lobules (free of visible infarction, calcification, hematoma or damage) and immediately frozen at −80˚C.

Mitochondrial studies were performed in CBMC and placental homogenates (5% w/v in mannitol buffer) [46] following quantification of protein content using the bybicinchoninic acid colorimetric assay (Thermo Scientific assay kit Prod #23225, Waltham, MA, USA) to normalize experimental measures [47].

**Cord blood and placental biomarkers analysis**

Cord blood plasmatic levels of B-type Natriuretic Peptide (BNP) were measured using the Siemens ADVIA Centaur BNP assay [48].

Mitochondrial toxicity was evaluated in CBMC and placental homogenates including relative content of mtDNA, cytochrome c oxidase (COX) and citrate synthase (CS) enzymatic activities. Total DNA was obtained by standard phenol-chloroform extraction procedure. A fragment of the mitochondrial-encoded 12SrRNA gene and the nuclear-encoded RNAse P gene were simultaneously amplified in triplicate by quantitative multiplex rtPCR using AbiPrism 7900 system from Applied Biosystems [49]. The relative content of mtDNA was expressed as the ratio between mitochondrial to nuclear DNA amount (12SrRNA mtDNA/ RNAseP nDNA content) as absolute values and as relative values normalized to mitochondrial mass through citrate synthase activity.
Spectrophotometric measurement of COX [EC 1.14.99.1] enzymatic activity was performed according to standardized international protocols [50] as well as CS activity [EC 4.1.3.7] measured as a surrogate of mitochondrial content [51,52]. Specific enzymatic activity was expressed in absolute values as nanomoles of synthesized substrate or consumed product per minute and milligram of protein (nmol/min.mg protein) units and as relative values normalized by CS activity, to relativize the enzymatic activity by mitochondrial content.

Statistical analysis
Data were analyzed using the IBM SPSS Statistics 21 statistical package. The results were expressed as mean ± standard deviation (SD), median [range] or percentage (n) as appropriate. Normality of data was ascertained with Kolmogorov—Smirnov test. Baseline comparisons between the study groups were performed using the Student t test. Categorical variables were analyzed using the Fisher’s exact test. Linear or logistic regression was performed to compare cardiac and mitochondrial parameters among groups adjusted by black ethnicity, low socioeconomic status, smoking during pregnancy and preterm delivery. A subanalysis according to the use of zidovudine during pregnancy was performed using linear regression analysis to test the mitochondrial toxic profile of this specific drug. P-values < 0.05 were considered statistically significant.

Results
Study population characteristics
From the initial eligible cohort, two pregnancies from the HIV-exposed group were excluded because of the diagnosis of fetal congenital heart disease (right aortic arch and left hypoplastic heart syndrome), with the final study population including 47 HIV-infected and 47 non-HIV-infected pregnant women. Both populations showed similar baseline epidemiological characteristics (Table 1) with the exception of a higher prevalence of black ethnicity, low socioeconomic status, smoking habit and hepatitis C among the HIV-infected women. Regarding perinatal outcome, HIV pregnancies showed a higher prevalence of preterm delivery and lower birth weight. No mother-to-child transmission of HIV occurred in the present cohort.

The immunovirological and therapeutic parameters of the HIV-infected pregnant population are shown in Table 2. Heterosexual transmission was the most common in our population followed by vertical transmission. Eight patients (17%) were diagnosed during pregnancy. Most patients were diagnosed and treated with cART before pregnancy (78.7%). During pregnancy, 46 patients (98%) received cART. The only patient not receiving cART was a late diagnosis after admission for preterm premature rupture of membranes and a subsequent preterm delivery. Regarding the type of NRTI used, 23.4% of the patients were treated with zidovudine. The most common NRTI combinations included: emtricitabine + tenofovir (51%); zidovudine + lamivudine (23.4%) and abacavir + lamivudine (23.4%). The mean CD4 cell count throughout pregnancy was >500 cells/μl. Most patients had an undetectable viral load during pregnancy (70.2% of patients at first trimester and 89.4% at third trimester). Among the five patients with a detectable viral load at delivery, four had less than 1000 copies/ml.

Fetal cardiovascular results
At the time of fetal echocardiography, the estimated fetal weight was similar between groups (HIV 1725 g (676) vs. non-HIV 1862 g (537), P = 0.297) with no signs of placental insufficiency (cerebroplacental ratio: HIV 2.05 (0.57) vs. non-HIV 2.33 (0.84), P = 0.071). Fetuses from
HIV-infected mothers showed larger and hypertrophic hearts (increased cardio-thoracic ratio and myocardial wall thicknesses) as compared to non-HIV-exposed fetuses. Moreover, 21% of fetuses from HIV-infected pregnancies presented mild pericardial effusion (2–4 mm). While the ejection fraction was preserved, fetuses from HIV-pregnancies also showed signs of decreased longitudinal motion (lower mitral S’) and impaired diastolic function (increased left isovolumic relaxation time) as compared to non-HIV-infected pregnancies. Most fetal cardiac changes remained statistically significant after adjustment by black ethnicity, low socioeconomic status, smoking during pregnancy and maternal hepatitis C infection (Table 3). Cord blood plasmatic BNP levels were significantly increased in the HIV cohort as compared to the non-HIV cohort (HIV 26.5 pg/ml (19.1) vs. non-HIV 19.3 pg/ml (12.3), p = 0.04), although statistical significance was lost after adjustment for maternal black ethnicity, smoking during pregnancy and preterm delivery (adjusted p = 0.85).

A subanalysis to investigate the impact of maternal cART on the fetal heart was further performed by subdividing the HIV-infected population according to the use of zidovudine during pregnancy. No differences were observed in maternal baseline characteristics, in perinatal outcomes or HIV-infection parameters among the study subgroups. Notably, a significant linear relationship was observed between maternal zidovudine exposure and fetal cardiac parameters.

### Table 1. Maternal baseline characteristics and perinatal outcome of the study populations.

|                         | HIV-infected pregnancies (N = 47) | Non HIV-infected pregnancies (N = 47) | p-Value |
|-------------------------|-----------------------------------|--------------------------------------|---------|
| **Maternal characteristics** |                                   |                                      |         |
| Age (years)             | 32.0 ± 5.9                         | 32.4 ± 5.8                           | 0.744   |
| Body mass index (kg/m²) | 24.7 ± 5.6                         | 24.5 ± 4.8                           | 0.938   |
| Black ethnicity         | 8 (17)                             | 0                                    | 0.009   |
| Nulliparity             | 20 (42.6)                          | 26 (55.3)                            | 0.144   |
| Low socioeconomic status| 17 (36.2)                          | 2 (4.3)                              | 0.001   |
| Smoking during pregnancy| 14 (29.8)                          | 5 (10.6)                             | 0.038   |
| Illicit substance use during pregnancy | 3 (6.4)                         | 0                                    | 0.052   |
| Comorbidity             | 1 (2.1)                            | 1 (2.1)                              | -       |
| Hepatitis C infection   | 6 (12.8)                           | 0                                    | 0.026   |
| Hepatitis B infection   | 2 (4.3)                            | 0                                    | 0.495   |
| **Pregnancy and perinatal outcome** |                       |                                      |         |
| Use of assisted reproductive technologies | 3 (6.4)                         | 2 (4.3)                              | 0.897   |
| Hemoglobin during pregnancy (g/dl) | 11.3 ± 1.12                   | 11.4 ± 0.91                          | 0.745   |
| Gestational diabetes    | 2 (4.3)                            | 2 (4.3)                              | -       |
| Preeclampsia            | 3 (6.4)                            | 3 (6.4)                              | -       |
| Small-for-gestational age| 6 (12.8)                        | 3 (6.4)                              | 0.487   |
| Preterm delivery        | 8 (17.0)                           | 1 (2.1)                              | 0.031   |
| Gestational age at delivery (weeks) | 37.6 ± 3.0                   | 39.5 ± 1.6                           | <0.001  |
| Cesarean section        | 34 (72.3)                          | 17 (36.2)                            | 0.002   |
| Birth weight (g)        | 2863 ± 691                         | 3288 ± 459                           | 0.001   |
| 5 minutes Apgar score   | 10 [4–10]                          | 10 [8–10]                            | 0.067   |
| Hospitalization in neonatal intensive care unit | 6 (12.8)                        | 1 (2.1)                              | 0.111   |
| Major neonatal morbidity| 1 (2.1)                            | 0                                    | 0.487   |
| Perinatal mortality     | 0                                  | 0                                    | -       |

Data are mean ± standard deviation (SD), median [range] or n (percentage).

HIV = Human Immunodeficiency Virus

https://doi.org/10.1371/journal.pone.0213279.t001
tendency to worse cardiovascular results among the subgroups was observed, with the subgroup receiving zidovudine showing the worst results. There was a significant trend to progressively thicker fetal myocardial wall thicknesses among the subgroups (left free wall thickness: non-HIV 2.61 mm (0.43) vs. HIV treated without zidovudine 3.10 mm (0.86) vs. HIV treated with zidovudine 3.34 mm (0.54), p < 0.01; and septal wall thickness: non-HIV 3.40 mm (0.59) vs. HIV treated without zidovudine 3.65 mm (0.87) vs. HIV treated with zidovudine 3.95 mm (0.71), p = 0.041) (Fig 1A).

In addition, IRT was significantly longer across groups (non-HIV 41.18 ms (7.9) vs. HIV treated without zidovudine 51.55 ms (9.19) vs. HIV treated with zidovudine 59.21 ms (9.35); p < 0.01).

Table 2. Immunovirological and therapeutic parameters among the HIV-infected pregnancies.

| HIV transmission                  | n = 47 |
|----------------------------------|-------|
| Heterosexual                     | 37 (78.7) |
| Vertical                         | 6 (12.8) |
| Injection drug use               | 4 (8.5) |
| Previous opportunistic infection | 13 (27.7) |
| HIV diagnosis in pregnancy       | 8 (17.0) |
| Opportunistic infection during pregnancy | 1 (2.1) |
| Months of HIV infection at delivery | 91 [0–324] |

| Infection parameters during pregnancy |          |          |
|---------------------------------------|----------|----------|
| CD4 cell count at first trimester (cells/μl) | 550 ± 197 |
| CD4 cell count at delivery (cells/μl)     | 548 ± 226 |
| Viral load <50 copies/ml at first trimester | 33 (70.2) |
| Viral load <50 copies/ml at delivery     | 42 (89.4) |
| Viral load at delivery (patients with detectable viral load copies/ml) | 331 [115–6500] |

| Antiretroviral treatment characteristics |          |          |
|-----------------------------------------|----------|----------|
| cART before pregnancy                   | 37 (78.7) |
| Weeks of cART before pregnancy          | 42 [0–307] |
| cART during pregnancy                   | 46 (97.9) |
| Weeks of cART during pregnancy          | 37.6 [15.2–41] |
| cART during first trimester pregnancy   | 34 (72.3) |
| NRTI during pregnancy                   | 46 (97.9) |
| Weeks of NRTI during pregnancy          | 37.3 [12.2–41] |
| Zidovudine during pregnancy             | 11 (23.4) |
| Zidovudine during first trimester       | 8 (17) |
| Weeks of zidovudine during pregnancy    | 36 [20.1–41] |
| Lamivudine during pregnancy             | 22 (46.8) |
| NNRTI during pregnancy                  | 14 (29.8) |
| Weeks of NNRTI during pregnancy         | 34.1 [5–40.5] |
| PI during pregnancy                     | 31 (66) |
| Weeks of PI during pregnancy            | 37.2 [10–41] |
| INI during pregnancy                    | 7 (14.9) |

Data are mean ± standard deviation (SD); median [range] or n (percentage) as indicated. HIV = Human Immunodeficiency Virus. cART: Combined antiretroviral treatment; NRTI: Nucleoside reverse transcriptase inhibitors; NNRTI: Non nucleoside reverse transcriptase inhibitors; PI: Protease Inhibitors; INI: Integrase inhibitors.

https://doi.org/10.1371/journal.pone.0213279.t002
Mitochondrial results
The cord blood mitochondrial content, represented by CS activity, was significantly increased in CBMC from HEU fetuses with respect to non-HIV-exposed fetuses (Table 4). Mitochondrial DNA content and function were preserved with similar levels of mtDNA and COX enzymatic activity. All the mitochondrial parameters studied in placental tissue were similar between the study populations.

The subanalysis according to the use of zidovudine (Fig 1B) revealed a significant linear tendency to progressively higher CS activity in HIV-infected pregnancies using zidovudine compared to HIV-infected pregnancies not using zidovudine and non-infected pregnancies (109.79 nmol/min.mg of protein (50.42) vs. 70.28 nmol/min.mg of protein (30.68) vs. 56.7 nmol/min.mg of protein (28.4) respectively; p = 0.026).

We found no significant correlation between mitochondrial data and maternal immunological status, fetal cardiovascular results or perinatal outcome.

Discussion
In the present study, we found signs of increased fetal myocardial mass and mitochondrial content most likely enabling a preserved cardiac ejection fraction and mitochondrial function in HEU fetuses exposed to maternal cART. Both cardiovascular and mitochondrial mass-related parameters were significantly associated with zidovudine exposure.

The present study confirms previous results suggesting the presence of fetal cardiac remodeling in HIV-infected pregnancies, mainly in the form of fetal myocardial hypertrophy. HIV-
exposed fetuses showed larger hearts with a higher prevalence of pericardial effusion, signs of increased myocardial mass, reduced systolic motion and impaired relaxation with preserved ejection fraction. These results are in agreement with previous literature in HEU fetuses [53] and suggest that fetal cardiac hypertrophy compensates for myocardial toxicity in the context of HIV infection and cART exposure. Indeed, the present study also confirms previous data.

Fig 1. Results on fetal myocardial thickness (A) and mitochondrial content -citrate synthase activity- (B) according to the maternal use of zidovudine. Box and whiskers graph of fetal myocardial left wall thickness (1A) and mitochondrial content -citrate synthase activity- (1B) among non HIV-infected and HIV-infected subdivided according to the use of zidovudine during pregnancy. A significant trend of increased myocardial thickness and mitochondrial content was observed among the categories. p-value was calculated by ANOVA test among the three categories. Boxes in the graphic represent 25th, 50th (band inside the box), and 75th centile values. Whiskers express dispersion (1.5×interquartile range).

https://doi.org/10.1371/journal.pone.0213279.g001
suggesting a significant association between fetal myocardial hypertrophy and the use of zidovudine during pregnancy [11].

This study also aimed to assess fetal and placental mitochondrial function in HIV pregnancies. We observed an increased CS activity in the fetal CBMC of the HIV-exposed group, with a similar mtDNA content and COX enzymatic activity. Citrate synthase activity is one of the biomarkers exhibiting the strongest association with mitochondrial content [52]. No differences were detected in any of the mitochondrial parameters in placental tissue between groups. Our results in cord blood may reflect impaired fetal mitochondrial function, which triggers a compensatory mechanism consisting of increasing the number of mitochondria to preserve a normal mitochondrial activity, as suggested in previous studies [54]. Interestingly, these results are concordant with the fetal cardiac findings. The hypertrophic pattern observed in the fetal echocardiography, with a higher myocardial mass, might enable a preserved global systolic function, reflected by a normal fetal ejection fraction. In addition, the CS activity in fetal CBMC, reflecting the mitochondrial content in fetal samples, similar to the hypertrophic phenotype described in the fetal cardiac evaluation, showed a significant positive correlation with the maternal use of zidovudine during pregnancy [11].

Table 4. Cord blood and placental mitochondrial results among the study groups. Data are mean ± standard deviation.

|                      | HIV-infected pregnancies (n = 47) | Non HIV-infected pregnancies (n = 47) | Adjusted p-Value* |
|----------------------|----------------------------------|-------------------------------------|-------------------|
| **Cord blood**       |                                  |                                     |                   |
| mtDNA (12SrRNA/RNaseP) | 95.2 ± 33.0                      | 90.4 ± 27.6                         | 0.654             |
| mtDNA/CS(12SrRNA/RNaseP normalized by CS) | 3.81 ± 2.29 | 4.20 ± 3.53 | 0.433 |
| COX activity (nmol/min.mg of protein) | 33.2 ± 20.2 | 30.8 ± 18.9 | 0.295 |
| CS activity (nmol/min.mg of protein) | 82.9 ± 40.5 | 56.7 ± 28.4 | 0.007 |
| COX/CS (nmol/min.mg of protein normalized by CS) | 0.44 ± 0.27 | 0.57 ± 0.29 | 0.530 |
| **Placenta**         |                                  |                                     |                   |
| mtDNA (12SrRNA/RNaseP) | 94.7 ± 19.1                      | 91.5 ± 26.7                         | 0.665             |
| mtDNA/CS (12SrRNA/RNaseP ratio normalized by CS) | 3.06 ± 1.22 | 2.95 ± 1.43 | 0.945 |
| COX activity (nmol/min.mg of protein) | 16.7 ± 6.02 | 17.9 ± 6.78 | 0.799 |
| CS activity (nmol/min.mg of protein) | 34.8 ± 13.1 | 33.7 ± 11.3 | 0.759 |
| COX/CS (nmol/min.mg of protein normalized by CS) | 0.50 ± 0.15 | 0.58 ± 0.24 | 0.353 |

mtDNA: mitochondrial DNA. CS: Citrate Synthase. COX: cytochrome c oxidase.

* P-value calculated by linear regression adjusted by black ethnicity, low socioeconomic status, smoking during pregnancy, maternal hepatitis C infection, C-section and birth weight.

https://doi.org/10.1371/journal.pone.0213279.t004

suggesting a significant association between fetal myocardial hypertrophy and the use of zidovudine during pregnancy [11].
associated with higher rates of adverse effects [32,33]. Therefore, we hypothesized that populations under relatively more toxic cART regimens would present impaired mitochondrial function, while other populations such as that in the present study receiving less toxic therapies could compensate and maintain function by increasing mitochondrial mass.

The present study has some strengths and limitations that merit comment. One of the main strengths is that this is the first work simultaneously assessing fetal cardiac morphology and function together with cord blood mitochondrial toxicity parameters in HIV-pregnancies. The comprehensive fetal cardiac evaluation demonstrated significant changes in cardiac structure and function in HIV-exposed fetuses. Moreover, the present study proposes a possible pathogenic mechanism involved in fetal cardiac abnormalities, with a new pattern of mitochondrial impairment in HEU fetuses under cART related to the use of zidovudine. We also acknowledge some limitations. Firstly, the relatively small sample size of the study could have hampered some statistical differences and limited further subanalysis among the HIV population. For instance, the correlation between fetal cardiac and mitochondrial results may have been hampered by the limited number of patients treated with zidovudine. Secondly, we acknowledge the potential influence of confounders such as maternal smoking status, concomitant infections or other pregnancy complications. However, a multivariate analysis was conducted in order to minimize a potential confounding effect. Regarding mitochondrial studies, despite platelet contamination cannot be totally discarded in the samples studied, its minimal representation, abrogates for negligible effects. Finally, mitochondrial function was studied in fetal CBMC and in placental homogenates, which may not reflect the real mitochondrial toxicity in the fetal heart. Therefore, future experimental studies directly evaluating fetal cardiac mitochondrial toxicity in animal models are needed.

In conclusion, in the present cohort we confirmed the presence of fetal cardiac hypertrophy and further report signs of increased mitochondrial number in HEU fetuses, being both associated with maternal zidovudine treatment during pregnancy. These results highlight the relevance of prenatal studies evaluating the impact of different cART regimens on HEU children in order to identify the safest options to be incorporated in the clinical management of these pregnancies. It also reinforces the concept of fetal programming that defines prenatal life as a critical period for fetal organ development during which any environmental change might affect and have an impact on future health. Further studies are warranted to evaluate the potential long-term impact on cardiovascular health in the constantly evolving HEU cohorts under different cART regimens.

Acknowledgments

We also wish to thank the collaboration and the valuable help of Ester Tobias as laboratory technician and Donna Pringle for language assistance.

Author Contributions

Conceptualization: Carol Esteve, Glòria Garrabou, Fàtima Crispi.

Data curation: Laura García-Otero.

Investigation: Laura García-Otero, Marta López, Constanza Morén, Berta Torres, Fátima Crispi.

Methodology: Laura García-Otero, Marta López, Mariona Guitart-Mampel, Constanza Morén, Anna Goncé, Laura Salazar, Glòria Garrabou, Fátima Crispi.

Supervision: Marta López, Fátima Crispi, Eduard Gratacós.
Writing – original draft: Laura García-Otero, Marta López, Fátima Crispi.

Writing – review & editing: Laura García-Otero, Marta López, Mariona Guitart-Mampel, Constanza Morén, Anna Goncé, Carol Esteve, Laura Salazar, Olga Gómez, Josep María Martínez, Berta Torres, Sergi César, Glòria Garrabou, Fátima Crispi, Eduard Gratacós.

References

1. UNAIDS (The Joint United Nations Programme on HIV/AIDS). Fact sheet- Latest statistics on the status of the AIDS epidemic. 2017.

2. Liotta G, Marazzi MC, Mothibi KE, et al. Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition Model. Int J Environ Res Public Health. 2015; 12(10):13224–13239. https://doi.org/10.3390/ijerph121013224 PMID: 26506365

3. Little KM, Taylor AW, Borkowf CB, et al. Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994–2010. Pediatr Infect Dis J. 2017; 36(1):66–71. https://doi.org/10.1097/INF.0000000000001355 PMID: 27749662

4. Moreton MA, Bertera F, Lagomarsino E, Riedel J, Chiappetta DA, Höcht C. Advances in therapy for the prevention of HIV transmission from mother to child. Expert Opin Pharmacother. 2017; 18(7):657–666. https://doi.org/10.1080/14656566.2017.1316369 PMID: 28390906

5. Desmonde S, Goetzhebuer T, Thorne C, Leroy V. Health and survival of HIV perinatally exposed but uninfected children born to HIV-infected mothers. Curr Opin HIV AIDS. 2016; 11(5):465–476. https://doi.org/10.1097/COH.0000000000000300 PMID: 27716731

6. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989; 2(8663):577–580. PMID: 2570282

7. Lipshultz SE, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989; 2(8663):577–580. PMID: 2570282

8. Wilkinson JD, Williams PL, Leister E, et al. Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. AIDS. 2015; 29(1):91–100. https://doi.org/10.1097/QAD.0000000000004949 PMID: 25562493

9. Lipshultz SE, Miller TL, Wilkinson JD, et al. Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: A view from the United States of America. J Int AIDS Soc. 2013; 16:18597. https://doi.org/10.7448/IAS.16.1.18597 PMID: 23782480

10. Lipshultz SE, Williams PL, Zeldow B, et al. Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. AIDS. 2015; 29(1):91–100. https://doi.org/10.1097/QAD.0000000000004949 PMID: 25562493

11. Garcia-Otero L, López M, Gómez O, et al. Zidovudine treatment in HIV-infected pregnant women is associated with fetal cardiac remodelling. AIDS. 2016; 30(9):1393–401. https://doi.org/10.1097/QAD.0000000000001066 PMID: 26919731

12. Guerra V, Leister EC, Williams PL, et al. Long-Term Effects of In Utero Antiretroviral Exposure: Systolic and Diastolic Function in HIV-Exposed Uninfected Youth. AIDS Res Hum Retroviruses. 2016; 32(7):621–627. https://doi.org/10.1089/AID.2015.0281 PMID: 26794032

13. Miro O, Lopez S, Martinez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis. United States; 2004; 39(5):710–716.

14. Koczin CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010; 6(12):1493–1504. https://doi.org/10.1517/17425255.2010.526602 PMID: 20929279

15. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995; 1(5):417–422. PMID: 7585087

16. Enns GM. Pediatric mitochondrial diseases and the heart. Curr Opin Pediatr. 2017; 29(5):541–551. https://doi.org/10.1097/MOP.0000000000000535 PMID: 28719387

17. Dadson K, Hauck L, Billia F. Molecular mechanisms in cardiomyopathy. Clin Sci. 2017; 131(13):1375–1392. https://doi.org/10.1042/CS20160170 PMID: 28649228

18. Shiramizu B, Shikuma KM, Kamemoto L, et al. Brief Report: Placenta and Cord Blood Mitochondrial DNA Toxicity in HIV-Infected Women Receiving Nucleoside Reverse Transcriptase Inhibitors During Pregnancy. JAIDS J Acquir Immune Defic Syndr. 2003; 32(4):370–374. PMID: 12640193
19. Noguera-Julian A, Morén C, Rovira N, et al. Decreased Mitochondrial Function Among Healthy Infants Exposed to Antiretrovirals During Gestation, Delivery and the Neonatal Period. Pediatr Infect Dis J. 2015; 34(12):1349–54. https://doi.org/10.1097/INF.0000000000000894 PMID: 26372453

20. Côté HCF, Raboud J, Bitoun A, et al. Perinatal Exposure to Antiretroviral Therapy Is Associated With Increased Blood Mitochondrial DNA Levels and Decreased Mitochondrial Gene Expression in Infants. J Infect Dis. 2008; 198(6):851–859. https://doi.org/10.1086/591253 PMID: 18684095

21. Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral Exposure and Lymphocyte mtDNA Content Among Uninfected Infants of HIV-1-Infected Women. Pediatrics [Internet]. 2009; 124(6):e1189–e1197. Available from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2008-2771

22. Morén C, Noguera-Julian A, Garrabou G, et al. Mitochondrial disturbances in HIV pregnancies. AIDS. 2015; 29(1):5–12. https://doi.org/10.1097/QAD.0000000000000486 PMID: 25268887

23. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003; 33(2):175–183. PMID: 12794551

24. Hernández S, Morén C, López M, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. AIDS. 2012; 26(4):419–28. https://doi.org/10.1097/QAD.0b013e32834f3232 PMID: 22156962

25. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001; 285(16):2083–2093. PMID: 11311097

26. Mannisto T, Mendola P, Vaaramaki M, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. United States; 2013; 127(6):681–690.

27. Peng TY, Ehrlich SF, Crites Y, et al. Trends and racial and ethnic disparities in the prevalence of pregestational type 1 and type 2 diabetes in Northern California: 1996–2014. Am J Obstet Gynecol. United States; 2017; 216(2):177.e1–177.e8.

28. Gomes V, Mesquita A, Capela C. Autoimmune diseases and pregnancy: analysis of a series of cases. BMC Res Notes. England; 2015; 8:216.

29. Mol BW, Roberts CT, Thangaratnam S, Magee LA, de Groot CJ HG. Pre-eclampsia. Lancet. 2016; 387:999–1011. https://doi.org/10.1016/S0140-6736(15)00070-7 PMID: 26342729

30. Figueras F, Meier E, Iraola A, et al. Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol. 2008; 136(1):20–24. https://doi.org/10.1016/j.ejogrb.2006.12.015 PMID: 17287065

31. World health organization. International statistical classification of diseases and related health problems, 10th revision (ICD-10). 2015;.

32. GESIDA/Spanish National AIDS study group. Guidelines for HIV control during pregnancy, delivery and prevention of Mother to Child Transmission. (Last updated March 22, 2013). [Accessed 15 Feb 2018].

33. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of ART in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Oct 2017.; Accessed (Feb 2018).

34. Hadlock FP, Shah YP, Kanon DJ, Lindsey J V. Fetal crown-rump length: reevaluation of relation to menstrual age (5–18 weeks) with high-resolution real-time US. Radiology. 1984; 150(2):535–540. https://doi.org/10.1148/radiology.150.2.6691115 PMID: 6691115

35. Baschat AA, Gebruch U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol. 2003; 21(2):124–127. https://doi.org/10.1002/uog.20 PMID: 12601821

36. Chauvié R, Bollmann R, Goldner B, Heling KS, Tenstedt C. Fetal cardiomegaly: echocardiographic findings and outcome in 19 cases. Fetal Diagn Ther. 1994; 9(2):92–104. https://doi.org/10.1159/000263915 PMID: 8185946

37. Kyeong K-S, Won H-S, Lee M-Y, Shim J-Y, Lee PR, Kim A. Clinical outcomes of prenatally diagnosed cases of isolated and nonisolated pericardial effusion. Fetal Diagn Ther. 2014; 36(4):320–325. https://doi.org/10.1159/000358591 PMID: 25270065

38. Rychlik J, Ayres N, Cuneo B, et al. American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram. J Am Soc Echocardiogr. 2004; 17(7):803–810. https://doi.org/10.1016/j.echo.2004.04.011 PMID: 15220910

39. Teichholz LE, Kreulen T, Herman M V, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976; 37(1):7–11. PMID: 1244736
41. Germanakis I, Pepes S, Sifakis S, Gardiner H. Fetal longitudinal myocardial function assessment by anatomic M-mode. Fetal Diagn Ther. 2012; 32(1–2):65–71. https://doi.org/10.1159/000330790 PMID: 22613840
42. Comas M, Crispi F, Gómez O, Puerto B, Figueras F, Gratacos E. Gestational age- and estimated fetal weight-adjusted reference ranges for myocardial tissue Doppler indices at 24–41 weeks’ gestation. Ultrasound Obstet Gynecol. 2011; 37(1):57–64. https://doi.org/10.1002/uog.8870 PMID: 21046540
43. Gardiner HM, Pasquini L, Wolfenden J, et al. Myocardial tissue Doppler and long axis function in the fetal heart. Int J Cardiol. 2006; 113(1):39–47. https://doi.org/10.1016/j.ijcard.2005.10.029 PMID: 16360223
44. Cruz-Martinez R, Figueras F, Bennasar M, et al. Normal reference ranges from 11 to 41 weeks’ gestation of fetal left modified myocardial performance index by conventional Doppler with the use of stringent criteria for delimitation of the time periods. Fetal Diagn Ther. 2012; 32(1–2):79–86. https://doi.org/10.1159/000330798 PMID: 22759646
45. Cossarizza A. Tests for mitochondrial function and DNA: Potentials and pitfalls. Curr Opin Infect Dis. 2003; 16(1):5–10. PMID: 12821823
46. Casademont J, Perea M, Lopez S, Beato A, Miro O, Cardellach F. Enzymatic diagnosis of oxidative phosphorylation defects on muscle biopsy: better on tissue homogenate or on a mitochondria-enriched suspension? Med Sci Monit. 2004; 10(9):CS49–53. PMID: 15328490
47. Bainor A, Chang L, McQuade TJ, Webb B, Gestwicki JE. Bicinchoninic acid (BCA) assay in low volume. Anal Biochem. 2011; 410(2):310–312. https://doi.org/10.1016/j.ab.2010.11.015 PMID: 21078286
48. Belenky A, Smith A, Zhang B, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004; 340(1–2):163–172. PMID: 14734208
49. Garrabou G, Moren C, Gallego-Escured JM, et al. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia. J Acquir Immune Defic Syndr. 2009; 52(4):443–451. https://doi.org/10.1097/QAI.0b013e3181bd564c PMID: 19779356
50. Medja F, Allouche S, Frachon P, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. Mitochondrion. 2009; 9(5):331–339. https://doi.org/10.1016/j.mito.2009.05.001 PMID: 19439198
51. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994; 228(1):35–51. PMID: 7955428
52. Larsen S, Nielsen J, Hansen CN, et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol. 2012; 590(14):3349–3360. https://doi.org/10.1113/jphysiol.2012.230185 PMID: 22586215
53. De la Calle M, Rodriguez R, Deiros L, Bartha JL. Fetal cardiac biometry and function in HIV-infected pregnant women exposed to HAART therapy. Prenat Diagn. 2015; 35(5):453–5. https://doi.org/10.1002/pd.4549 PMID: 25512023
54. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med. 2012; 13(2):98–106. https://doi.org/10.1111/j.1468-1293.2011.00945.x PMID: 22103263
55. Cote HCF, Brumme ZL, Craib KJP, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002; 346(11):811–820. https://doi.org/10.1056/NEJMoa012035 PMID: 11893792
56. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000; 22(6):685–708. https://doi.org/10.1016/S0149-2918(00)90004-3 PMID: 10929917